Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Vaxil Bio Ltd V.VXL

Alternate Symbol(s):  VXLLF

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.


TSXV:VXL - Post by User

Post by Red~Oneon Feb 11, 2021 10:57am
95 Views
Post# 32537557

Mucin 1 Market is Expected to Grow with an Impressive CAGR t

Mucin 1 Market is Expected to Grow with an Impressive CAGR t

Mucin 1 Market is Expected to Grow with an Impressive CAGR till 2027 


Summary of the Report

Mucin 1 Market Key Dynamics-

Mucin 1 Market was valued at XX$ bn in 2019. Basis above findings and observations, our team has derived a robust CAGR of XX % from 2020 to 2027, expected to have a spiralling rise enfolding in next five to seven years.

According to Decisive Markets Insights, Global Market size would be increasing at rapid pace during the forecast period, i.e., 2020 to 2027, experiencing a substantial growth rate from 2020 – 2027.

Market Dynamics Impacting the Market Growth

To know more about the report, visit @ https://decisivemarketsinsights.com/mucin-1-market/58611073/request-sample

By Market Players:

Akshaya Bio Inc
Transgene SA
Etubics Corp
Bavarian Nordic A/S
Minerva Biotechnologies Corp
Boehringer Ingelheim GmbH
Merck KGaA
GeoVax Labs Inc
Vaxil Bio Therapeutics Ltd

By Type

TG-4010
GO-2032c
ImMucin
BI-1361849
Others

By Application

Prostate Cancer
Breast Cancer
Colon Cancer
Ovarian Cancer
Others

Mucin 1 Market dynamics has a key role to play in a market as the current rend and forecast along with the estimates are largely based on these factors. So, we have examined the drivers, restraints and opportunities in detail for this particular market as to get a clear picture about the growth and trend of this market. Moreover, we have also analyzed the impact analysis of the drivers and restraints in all short term, medium term and long term. In addition, the key opportunistic areas have also been identified across application and geography segments as it would help the manufacturers have a vibrant picture about the market.

COVID -19 and its Impact Analysis
• COVID -19 pandemic scenario before spread
• COVID -19 pandemic scenario at present
• COVID -19 pandemic scenario post recovery

<< Previous
Bullboard Posts
Next >>